Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00939523 · MORE INFO

Limitations, agreements, and source contact

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy · Source last updated 2020-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
For one of the secondary outcomes, the ErbB receptor expression, only 3 subjects had tumor specimens available to immunostain. Therefore, only results on 3 subjects were reported for this outcome.
point Of Contact
email
coopero@cshs.org
organization
Cedars-Sinai Medical Center
phone
310-423-4774
title
Odelia Cooper
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
For one of the secondary outcomes, the ErbB receptor expression, only 3 subjects had tumor specimens available to immunostain. Therefore, only results on 3 subjects were reported for this outcome.
point Of Contact
email
coopero@cshs.org
organization
Cedars-Sinai Medical Center
phone
310-423-4774
title
Odelia Cooper

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice